Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections

Sara Alosaimy, Sarah C.J. Jorgensen, Abdalhamid M. Lagnf, Sarah Melvin, Ryan P. Mynatt, Travis J. Carlson, Kevin W. Garey, David Allen, Veena Venugopalan, Michael Veve, Vasilios Athans, Stephen Saw, Christine N. Yost, Susan L. Davis, Michael J. Rybak

Producción científica: Articlerevisión exhaustiva

36 Citas (Scopus)

Resumen

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

Idioma originalEnglish (US)
Número de artículoofaa051
PublicaciónOpen Forum Infectious Diseases
Volumen7
N.º3
DOI
EstadoPublished - mar 1 2020
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Huella

Profundice en los temas de investigación de 'Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections'. En conjunto forman una huella única.

Citar esto